Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 18,593 clinical trials
P Prof. Christian Thomas, MD

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two …

18 - 100 years of age Both Phase 3

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

18 - 70 years of age Both Phase 2
S Site Public Contact

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

45 - 74 years of age Female Phase 3
D Daniele Marrelli

Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer

In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.

18 - 80 years of age Both Phase 3
D Da Zhou, MD

Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer

Gastric cancer patients with stage III will be randomized to immune nutrition support or control group at discharge after total gastrectomy. Patients will receive 6 months of immune nutrition support or normal diet after discharge. The primary and secondary outcomes will be collected.

18 - 100 years of age Both Phase N/A
W Wendy Landier, PhD

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent HPV infection. An effective vaccine exists that can prevent these cancers, …

9 - 100 years of age Both Phase N/A
Y Yuan Li, Doctor

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

BACKGROUND In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment. However, 20 to 30 % of these patients will develop distant metastasis, which ultimately result in death. Perioperative chemotherapy is …

18 - 75 years of age Both Phase 3
C Cécile Bielmann

Evaluation of Lung Cancer CT Screening Performance Among Former and Current Smokers

Diagnostic performance of low-dose chest CT scan combined with lung-RADS classification (version 1.1) for lung cancer screening among former and current smokers.

50 - 80 years of age Both Phase N/A

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.

18 - 100 years of age Both Phase 1
U US GSK Clinical Trials Call Center

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.

18 - 100 years of age Both Phase 1

Rewrite in simple language using AI